Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES (ABT)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Abbott Laboratories : Abbott and AbbVie Announce Investor Calls

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/14/2013 | 04:10pm CEST

Abbott Park, Illinois and North Chicago - Abbott (NYSE: ABT) will announce its fourth-quarter and full-year 2012 financial results on Wednesday, Jan. 23, 2013, before the market opens.

Abbott's quarterly and annual results will include contributions from the company's former research-based pharmaceutical business, which became AbbVie on Jan. 1, 2013. While these results will be captured in a single press release, both companies will host separate conference calls to discuss their respective business results and 2013 outlooks.

Abbott will host a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) on Jan. 23, 2013. It will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available after 11 a.m. Central time.

On Wednesday, Jan. 30, 2013, AbbVie will host a live webcast at 8 a.m. Central time (9 a.m. Eastern) accessible through AbbVie's Investor Relations website at www.abbvieinvestor.com. An archived edition of the call will be available after 11 a.m. Central time.

About Abbott

Abbott (NYSE: ABT) is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 70,000 people.

About AbbVie

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. With its 125-year history, the company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. In 2013, AbbVie employs approximately 21,000 people worldwide and markets medicines in more than 170 countries.www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

Abbott Contacts:
Media:
Scott Stoffel

(847) 936-9502
Financial:
Brian Yoor

(847) 937-6343
AbbVie Contacts:
Media:
Adelle Infante

(847) 938-8745
Financial:
Larry Peepo

(847) 935-6722
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
05/25ABBOTT LABORATORIES : Trademark Application for "PHOSPHAGEN" Filed by Abbott Lab..
AQ
05/25ABBOTT LABORATORIES : Trademark Application for "COMMITTED TO THE C.A.S.E." File..
AQ
05/25ABBOTT LABORATORIES : Patent Issued for Cellular Analysis of Body Fluids (USPTO ..
AQ
05/25ABBOTT LABORATORIES : Patent Issued for Nutritional Supplement Powder (USPTO 996..
AQ
05/24ABBOTT LABORATORIES : Investigational tendyne device for mitral valve replacemen..
AQ
05/24ABBOTT LABORATORIES : - newest generation of leading heart stent is now approved..
AQ
05/24ABBOTT LABORATORIES : Real-World Study Results Support Use of Abbott's AMPLATZER..
PU
05/23ABBOTT LABORATORIES : Newest Generation of Leading Heart Stent is Now Approved i..
PR
05/23ABBOTT : 's Investigational Tendyne™ Device for Mitral Valve Replacement D..
PR
05/23ABBOTT LABORATORIES : $96,439 Federal Contract Awarded to Abbott Laboratories
AQ
More news
News from SeekingAlpha
05/23Abbott's Tendyne mitral valve shows positive effect in global study 
05/22Abbott's stent guide improved outcomes in long-term study 
05/18MeiraGTx Aims For $86 Million U.S. IPO 
05/16THE 30+1 PORTFOLIO : An Average Investor's Reasoning For Buying A Stock 
05/03My Dividend Growth Portfolio - 42 Holdings, 4 Buys 
Financials ($)
Sales 2018 30 950 M
EBIT 2018 6 458 M
Net income 2018 2 536 M
Debt 2018 15 152 M
Yield 2018 1,79%
P/E ratio 2018 47,86
P/E ratio 2019 33,96
EV / Sales 2018 4,02x
EV / Sales 2019 3,71x
Capitalization 109 B
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 68,5 $
Spread / Average Target 9,9%
EPS Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Brian Bernard Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Glenn Fletcher Tilton Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES9.53%109 346
JOHNSON & JOHNSON-11.45%325 801
PFIZER-0.91%208 713
NOVARTIS-8.30%194 397
ROCHE HOLDING LTD.-9.17%189 708
MERCK AND COMPANY5.01%158 970